May 2016

New Product - Lynparza

Lynparza (olaparib) is an orally active potent inhibitor of human poly (ADP ribose) polymerase (PARP) enzymes. Olaparib is indicated as monotherapy for the maintenance treatment of patients with platinum sensitive relapsed BRCA mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum based chemotherapy. Prior treatment must have included at least 2 courses of platinum based regimens. Lynparza is available as 50 mg capsules in a carton containing 4 bottles of 112’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629